1. Scrip
  2. >>Focus On Asia

Japan Approves Leqembi, All Eyes Now On Extended Pricing Discussions

Concizumab, Tenapanor, Others Get Nods

 
• By Lisa Takagi

Japan's latest batch of product approvals includes high-profile Alzheimer's drug Leqembi (lecanemab), along with Alhemo (concizumab) for hemophilia, Phozevel (tenapanor) for hyperphosphatemia and others. Eyes are now on the shape of use guidelines and monitoring requirements for Leqembi, along with how its extended NHI  reimbursement pricing process will develop. All going well, it could reach the market by the end of the year.

Japan is going to discuss leqembi's pricing with wide range of effects including cutting down nursing costs.
Japan to discuss Leqembi's pricing from a broad perspective including its potential reduction of care costs • Source: Shutterstock

Japan’s Ministry of Health, Labour and Welfare (MHLW) granted formal approval to a batch of 23 drugs on 25 September, including several important new therapies for Alzheimer's disease and hyperphosphatemia, along with several biosimilars.

Following a positive recommendation from a ministry advisory panel in August, Eisai Co., Ltd./Biogen, Inc.’s high-profile Alzheimer's drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By Lisa Takagi

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Activist Investor Vs. Japan Pharma: ASKA Plans Poison Pill As Dalton Pushes For MBO

 
• By Lisa Takagi

While ASKA plans to dilute the holding of largest investor Dalton by issuing new shares, the US investment firm continues to push a management buyout option to the mid-sized Japanese pharma company.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By Lisa Takagi

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.

More from Focus On Asia

Sino Biopharm Scoops LaNova In Chinese Pharma’s Biggest Biotech Buyout So Far

 
• By Dexter Jie Yan

Sino Biopharm will pay almost $1bn to acquire what target LaNova’s CEO described as an “exploding” pipeline, which includes six clinical-stage candidates in the oncology area.

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By Lisa Takagi

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 
• By Anju Ghangurde

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?